Collaborations

Alliance Medical Radiopharmacy

Radboud Translational Medicine and Alliance Medical started a collaboration in 2018 for the development, production and sales of radiopharmaceuticals.

Alliance Medical consists of the Diagnostic Imaging en Radiopharmaceuticals divisions.

Alliance Medical Diagnostic Imaging, a European operating organization with over 3,000 employees, combines service excellence en innovative medical imaging technology to support optimal patient treatment. It does its by using MRI, CT and PET/CT systems in both mobile units and fully equipped state-of-the-art diagnostic centers.

Alliance Medical Radiopharmaceuticals has an extensive network of cyclotron facilities in several European countries for the production, distribution and sales of radiopharmaceuticals. Thanks to this network, it can always offer the best possible solution to its customers. Through this collaboration, we aim to optimally meet the needs of hospitals'Nuclear Medicine departments and thus contribute to further optimization of medical imaging.

Quirem Medical

Radboud Translational Medicine and Quirem Medical have started a collaboration for the production of QuiremSpheres®. RTM will perform the final steps in the production process: from dispensing of the product vials to Quality Control of the final product. QuiremSpheres® are tiny radioactive spheres based on the radioactive isotope holmium-166. They are indicated for the treatment of advanced unresectable liver tumors by means of radioembolization.

QuiremSpheres® consists of biocompatible poly-L-lactic acid (PLLA) microspheres containing holmium-166, which is a high-energy beta-emitting isotope with gamma emission. The microspheres have a mean diameter of 30 micrometer (97% between of 15 to 60 micrometer). Due to the average diameter of 30 micrometer, the microspheres lodge preferentially in the microvasculature surrounding the tumor, maximising tumourcidal effects and minimising the effects on healthy liver parenchyma. The half-life of QuiremSpheres® is 26.8 hours, which means that more than 90% of the radiation is delivered within the first 4 days following the implantation procedure.

Once the microspheres have reached the tumor they will emit their beta radiation and destroy tumor cells, while the low energy gamma radiation passes through and out of the body and can be imaged by gamma-cameras. This unique property makes it possible to determine the distribution of QuiremSpheres® inside the patient with high resolution. In addition, the metal holmium can be visualized with MR imaging.

QuiremSpheres® microspheres have the same mode of action as existing Yttrium-90 based radioembolization products: the microspheres emit beta radiation that kills tumor cells from close range. In addition, QuiremSpheres® can be visualized with SPECT and MR imaging, even in low concentrations. This is unique and cannot be done with currently available Yttrium-90 based microspheres.

ImaginAb

The collaboration between RTM (Radboud Translational Medicine) and ImaginAb began in March 2020:

'As one of our Contract Development and Manufacturing Organizations (CDMOs), RTM has been instrumental in producing 89Zr Crefmirlimab Berdoxam doses for distribution to clinical sites across Europe. By January 2022, RTM was fully qualified to manufacture doses for ImaginAb, and it is anticipated that they will produce over 100 doses in 2024.

This partnership is advantageous as it enhances ImaginAb’s dose manufacturing capabilities in Europe, ensuring a more robust supply chain for our clinical studies, including those conducted by ImaginAb, Pharma, and Investigator-Initiated Trials (IITs).'